|P. O. Box 219078 , Kansas City, MO 64121|
|Fund Manager||Team Managed|
The Fund's investment objective is long-term growth of capital. The Fund invests, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of European issuers, and in derivatives and other instruments that have economic characteristics similar to such securities. The Fund uses various criteria to determine whether an issuer is in Europe, including whether (1) it is organized under the laws of a country in Europe; (2) it has a principal office in a country in Europe; (3) it derives 50% or more of its total revenues from business in countries in Europe; or (4) its securities are trading principally on a security exchange, or in an over-the-counter market, in a country in Europe. The Fund invests primarily in equity securities and depositary receipts. The principal types of equity securities in which the Fund invests are common and preferred stock. The Fund invests primarily in securities of issuers that are considered by the Fund s portfolio managers to have potential for earnings or revenue growth. The Fund may invest in the securities of issuers of all capitalization sizes, and may invest a significant amount of its net assets in the securities of small- and mid-capitalization issuers. The Fund may invest up to 100% of its assets in foreign securities, including up to 35% of its net assets in securities of European issuers located in emerging markets countries, i.e., those that are generally in the early stages of their industrial cycles. The Fund can invest in derivative instruments, including forward foreign currency contracts and futures contracts. The Fund can use forward foreign currency contracts to hedge against adverse movements in the foreign currencies in which portfolio securities are denominated; though the Fund has not historically used these instruments. The Fund can use futures contracts to gain exposure to the broad market in connection with managing cash balances or to hedge against downside risk. The portfolio managers employ a disciplined investment strategy that emphasizes fundamental research. The fundamental research primarily focuses on identifying quality growth companies and is supported by quantitative analysis, portfolio construction and risk management. Investments for the portfolio are selected bottom-up on a security-by-security basis. The focus is on the strengths of individual issuers, rather than sector or country trends. The portfolio managers strategy primarily focuses on identifying issuers that they believe have sustainable earnings growth, efficient capital allocation, and attractive prices. The Fund s portfolio managers may consider selling a security for several reasons, including when (1) its price changes such that they believe it has become too expensive, (2) the original investment thesis for the company is no longer valid, or (3) a more compelling investment opportunity is identified.
|Asset Type||% Of Allocation|
|Total Net Assets||371.69 M|
|Criteria||3 Years||5 Years||10 Years|
|Minimum Initial IRA||$250|
|Timeframe||Average Annual Current Performance Monthly As Of 08/31/2021||Average Annual Current Performance Quarterly As Of 06/30/2021||Avg Annual Current Performance Monthly As Of 08/31/2021||Avg Annual Current Performance Quarterly As Of 06/30/2021|
|Life Of Fund||
|Symbol||Company Name||% Of Assets|
|DB1||DEUTSCHE BOERSE AG||2.84%|
|ULE:LN||ULTRA ELECTRONICS HOLDINGS||2.83%|
|FBK.MI||FINECO BANK SPA||2.79%|
|SCHN.PA||SCHNEIDER ELECTRIC SA||2.76%|
|IGG.L||IG GROUP HOLDINGS PLC||2.59%|
|PRX AS||PROSUS NV||2.55%|
|PM||PHILIP MORRIS INTERNATIONAL||2.32%|
|INVEb.ST||INVESTOR AB B SHARES||2.28%|
Join the Action Alerts PLUS Community today!
'Redwire offers a diversified portfolio of space components that are well-positioned to capture emerging trends,' Jefferies says.
Uncertain fiscal and monetary policies could prompt a stock correction, the noted bull Phil Orlando says.
Sanofi says its COVID vaccine candidate has positive test results, but the company is ready to drop its development because of the Moderna and Pfizer vaccines.
Roku's 'unique position as a neutral player with a large installed base should allow it to continue gaining market share,' Bank of America says.
Aurora Cannabis had a tough quarter, but Cowen analysts still expect strong growth margins in 2022.
Identity-management provider Okta was upgraded to overweight at Morgan Stanley amid rebounding demand.
Failure to lift the $28.4 trillion debt ceiling this week could put the U.S. at risk of default as early as October 18, Treasury Secretary Janet Yellen told Senate lawmakers Tuesday.
AMAT's valuation 'is still very reasonable,' New Street says. 'But we don’t see a near-term catalyst for a rerating.'